Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide:

Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a recently approved single-tablet antiretroviral regimen and is recommended as a first-line agent. No cases of gynecomastia were rep...